Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Med.

Sec. Regulatory Science

The status quo of development of decentralized clinical trials

Provisionally accepted
Xiaoliang  ChenXiaoliang Chen1Mingxuan  ZhaoMingxuan Zhao2Na  LeiNa Lei3Lichun  DongLichun Dong2Qiang  LvQiang Lv4Jiashi  SunJiashi Sun5Jianchang  HeJianchang He6*Xianglin  ZhangXianglin Zhang1*
  • 1Shenyang Pharmaceutical University, Shenyang, China
  • 2The Affiliated Anning First People's Hospital of Kunming University of Science and Technology, Kunming, China
  • 3Yunnan University of Chinese Medicine, Kunming, China
  • 4Center For Drug and Medical Device Evaluation of Yunnan Province, Kunming, China
  • 5Center For Food and Drug Inspection of Yunnan Province, Kunming, China
  • 6First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, Kunming, China

The final, formatted version of the article will be published soon.

Decentralized clinical trials (DCTs) have emerged as a transformative model in new drug development, offering alternatives to traditional site-based trials through the integration of digital technologies and remote processes. This literature review examines the current landscape of DCTs by academic studies, policy reports, and regulatory guidance from major global regions. The review identifies and discusses the opportunities and challenges of DCTs, including scientific and operational innovation, equity and accessibility, governance and trust, sustainability and infrastructure. A comparative analysis of regulatory frameworks and guidance issued by different regulatory authorities all around the world reveals both convergences and distinctions in how DCTs are approached, particularly in areas such as digital health technologies or patient-centered model. The U.S. emphasizes efficiency and technological integration; the EU prioritizes equity and patient engagement; while China focuses on rare diseases, reducing regional disparities, and maintains a more cautious regulatory approach. The review concludes by identifying the need for greater international coordination and harmonization to fully realize the potential of DCTs while addressing their inherent risks. Building on observed regional differences, it further examines the challenges associated with harmonization, the implications of fragmented governance across jurisdictions, and the lessons learned from pilot implementations. These insights aim to inform future efforts toward more cohesive and globally aligned DCT frameworks.

Keywords: Decentralized clinical trials, Digital health technology, Transformative model, DCTs, Digital clinical trials

Received: 23 Jul 2025; Accepted: 04 Nov 2025.

Copyright: © 2025 Chen, Zhao, Lei, Dong, Lv, Sun, He and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Jianchang He, hejc@yn-cprc.com
Xianglin Zhang, xlz_acad@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.